EOFlow has submitted a 510(k) application to the regulator for the disposable insulin pump. Credit: E Eeasyc from Pixabay.

EOFlow is seeking approval from the US Food and Drug Administration (FDA) for its wearable disposable insulin pump, EOPatch.

The company has submitted a 510(k) application to the regulator for the disposable insulin pump to enter the US market.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

EOPatch insulin pump was launched in Korea in April last year.

In September this year, the company introduced this wearable disposable insulin pump in Europe.

EOFlow also secured approval for the pump in UAE during the same month, while in Indonesia in October.

See Also:

At present, the company is negotiating terms with the US distributors and plans to sign a distribution agreement within the first half of next year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

EOFlow founder and CEO Jesse Kim said: “I am very proud to begin the US clearance process. With this submission we have taken a major step forward in entering the world’s largest diabetes market.

“Furthermore, as the 510(k) device shares a common backplane with all EOFlow products, this submission is an important step in our efforts to commercialise extended wear and closed loop systems in the US.”

Last month, the company stated that it had developed the prototype of a seven-day wearable pump and advanced it to productisation.

The next-generation ‘EOPatch 3.0’, which is expected to be launched in 2024, has been evaluated in various tests with samples that have a 3ml reservoir. It can be operated for seven days based on EOFlow’s pumping technology,

The ‘EOPatch’, which is currently filed to the FDA, has a reservoir size of 2ml.

Furthermore, the company already received breakthrough device designation from FDA for a wearable integrated ‘artificial pancreas‘ solution.

It is a wearable disposable device that features a glucose monitoring sensor, an insulin pump and an integrated automated insulin delivery algorithm.